It will be available as an option for people with relapsing-remitting MS (RRMS), the most common form of the condition which ...

A long-term study has identified a potential biomarker that could help detect which patients are progressing toward more severe forms of multiple sclerosis.

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

NICE has said Biogen's Tysabri can now be used by the NHS in England and Wales to treat highly active relapsing-remitting ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...

Thousands of people in England with a type of multiple sclerosis (MS) are set to benefit from a new treatment on the NHS.

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

By analysing MRI scans and a simple blood test from hundreds of patients, researchers identified patterns that reveal how ...